Pulse ·
COVID vaccines: who still gets them free from October 2026
From 1 October 2026, government-funded COVID-19 vaccination is restricted to adults 75 and over, adults aged 65–74, Aboriginal and Torres Strait Islander people aged 50–74, and adults aged 18–64 with severe immunocompromising conditions. Working-age Australians outside these groups will pay out of pocket — expected to cost significantly more than the $25–35 annual influenza vaccine.
The government describes the change as a shift from the emergency pandemic programme to a long-term routine schedule targeted at those at highest risk of severe COVID-19. People outside the eligible group who want COVID-19 protection will need to discuss timing and value with their GP as a private vaccination.
The pandemic emergency is formally over. That is the government framing behind a significant vaccination policy change that takes effect on 1 October 2026.
From that date, most Australians will no longer receive COVID-19 vaccines for free. The government-funded programme narrows to a defined group: adults 75 and over (two doses annually, roughly six months apart), adults aged 65–74 (one dose yearly), Aboriginal and Torres Strait Islander people aged 50–74 (one dose yearly), and adults aged 18–64 with severe immunocompromising conditions such as dialysis-dependent kidney failure (one dose yearly).
Everyone outside that group — including the healthy 54-year-old, the 45-year-old with well-controlled asthma, the teacher who has had four vaccines and wants a fifth — will now need to pay. The cost has not yet been confirmed. A pharmaceutical industry spokesperson noted it may not be known until the last week of September, and anticipated it would be significantly more expensive than the typical $25–35 annual influenza vaccine.
That uncertainty is its own clinical and administrative challenge. Patients will ask. And many will ask this week.
Why this matters for general practice right now
The question you will hear most often is some version of: Do I still get a free COVID vaccine?
The answer for most patients is no.
The groups that do remain eligible — and who may not know they are — include patients on dialysis, solid organ transplant recipients, those with haematological malignancies, and others meeting the severe immunocompromise criteria. For older Aboriginal and Torres Strait Islander patients, eligibility continues to age 74. For adults 65 and over, free annual vaccination continues under the new programme.
For everyone else, the conversation has changed. It is no longer “when is your next free COVID vaccine?” It is a discussion about personal risk, cost-benefit, and whether a private vaccination is worth pursuing once pricing is confirmed.
That is a different kind of consultation, and it is worth being ready for it.
The case for this change
The government’s stated rationale — a shift from emergency pandemic response to a long-term routine programme focused on those at highest risk — is coherent public health policy. Mass vaccination during an emergency serves a different purpose than ongoing targeted immunisation in an endemic context. The four-plus years of universal free access represented an emergency posture that was always going to be wound back.
The groups that remain funded are genuinely at the highest risk of severe outcomes from COVID-19. There is also a resource-allocation argument for concentrating vaccine funding where the benefit is clearest. The evidence that COVID-19 vaccination provides meaningful additional protection to healthy adults under 65 against currently circulating strains is more limited than it was for the ancestral or early Omicron variants.
Targeted programmes for high-risk groups are the standard model for most vaccine-preventable diseases in Australia. COVID-19 vaccination becoming subject to the same logic represents a normalisation of the programme, not an abandonment of it.
The case against
The transition creates a cost barrier where none previously existed, at a moment when COVID-19 has not disappeared. The virus continues to circulate and continues to hospitalise people in the 45–64 age group — the same group now being asked to self-fund protection.
The pricing uncertainty compounds this. A patient who might have accepted a modest out-of-pocket cost will hesitate when no figure is quoted. “Significantly more than the flu vaccine” is not a number a patient can plan around. There is a real risk that patients in the middle-risk group — those with obesity, moderate respiratory disease, or multiple comorbidities that fall just short of the eligibility threshold — will opt out not because they have considered the evidence and declined, but because the cost friction is too high.
The equity dimension is only partially addressed. Aboriginal and Torres Strait Islander Australians are protected to age 74 — that is good policy. The lower-income working-age adult with type 2 diabetes or mild chronic obstructive pulmonary disease, just below the severe-immunocompromise bar, is not covered. That gap is worth naming when it is raised in your consulting room.
2 cents this week
Review your list before October 1. Identify patients whose conditions may qualify them for continued government-funded vaccination under the severe immunocompromise criteria. Make sure their records clearly document the qualifying condition. Patients who assumed they would be recalled automatically may not know they still qualify.
Have a clear, neutral script ready. For patients outside the eligible group, something like: “The government programme now focuses on the highest-risk groups. You’re no longer automatically covered. If you’d like to discuss whether a private COVID vaccine makes sense for you, we can do that.” Avoid framing this as an abandonment — it isn’t — but don’t minimise the real cost shift, particularly for patients on a limited income.
Brief reception staff now. The administrative load of this transition will arrive before the clinical workload. Once pricing is confirmed, make sure the front desk can answer first-wave queries without routing everything to the GP.
COVID-19 is no longer the emergency it was. The programme that matched that emergency is being scaled back accordingly. Most patients will accept that framing once someone explains it clearly. General practice is where they will come for that explanation first.
Verdict: yes — essential to communicate this week, before 1 October.
Sources cited
Frequently asked questions
-
My patient is 60 with type 2 diabetes — do they still get a free COVID vaccine from October 2026?
Type 2 diabetes alone does not qualify a 60-year-old for government-funded COVID-19 vaccination under the October 2026 criteria. The eligible conditions in the 18–64 group require severe immunocompromise — for example, dialysis-dependent chronic kidney disease, solid organ transplant, or active haematological malignancy. Well-controlled type 2 diabetes without complications does not meet this threshold. These patients can still access COVID vaccination as a private purchase; exact cost was not confirmed as of publication but is expected to exceed the $25–35 influenza vaccine price point.
-
Can GPs still administer COVID vaccines privately from October 1?
Yes. GPs can administer COVID-19 vaccines privately. Patients who no longer qualify for the government-funded programme can purchase vaccination through their GP practice at a private price, which will vary by practice. Pricing and product availability for the private programme were not confirmed at time of publication — watch for updates from RACGP and the relevant pharmacy dispensing bulletins before October 1.